Unichem Laboratories Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Pabitra Kumar Bhattacharya

İcra Kurulu Başkanı

₹29.2m

Toplam tazminat

CEO maaş yüzdesi	64.3%
CEO görev süresi	1.3yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	12.3yrs
Yönetim Kurulu ortalama görev süresi	1.3yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Pabitra Kumar Bhattacharya'un ücretlendirmesi Unichem Laboratories'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-₹56m
Jun 30 2024	n/a	n/a	-₹606m
Mar 31 2024	₹29m	₹19m	-₹705m

Tazminat ve Piyasa: Pabitra Kumar 'ın toplam tazminatı ($USD 345.49K ) Indian pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 355.26K ).

Tazminat ve Kazançlar: Pabitra Kumar şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Pabitra Kumar Bhattacharya (55 yo)

1.3yrs

Görev süresi

₹29,175,000

Tazminat

Mr. Pabitra Kumar Kalipada Bhattacharya had been Managing Director of Krebs Biochemicals & Industries Limited since August 1, 2021 until August 9, 2023 and had been its Additional Director since July 30, 2...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Pabitra Kumar Bhattacharya	MD & Director	1.3yrs	₹29.18m	Veri yok
Pradeep Bhandari	Head of Legal	5.3yrs	₹9.84m	Veri yok
Dhananjay Sathe	Chief Scientific & Compliance Officer	no data	Veri yok	Veri yok
Prasad Joshi	Vice President of Human Resources & ER	16.4yrs	₹7.48m	Veri yok
Vinod Behl	Head of Projects & Investments	no data	₹2.10m	Veri yok
Jalesh Burye	Chief Quality & Compliance Officer	no data	Veri yok	Veri yok
Ashwani Kumar	Chief Manufacturing & Compliance Officer	no data	Veri yok	Veri yok
Bhagwat Dhingra	Chief Executive of Domestic Pharma	12.3yrs	₹13.62m	Veri yok
Scott Delaney	President of North America & CEO of North America	6.4yrs	Veri yok	Veri yok
P. Deshpande	Vice President of Chemical of Research and Development	no data	₹593.35k	Veri yok
Gajendra Ghanekar	Vice President of Commercial	24yrs	₹6.14m	Veri yok
R. Shapeti	Advisor of Active Pharmaceutical Ingredients (API)	no data	₹5.24m	Veri yok

12.3yrs

Ortalama Görev Süresi

65.5yo

Ortalama Yaş

Deneyimli Yönetim: 506690 'un yönetim ekibi deneyimli ve deneyimlidir ( 12.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Pabitra Kumar Bhattacharya	MD & Director	1.3yrs	₹29.18m	Veri yok
Prakash Mody	Chairman	50.4yrs	₹328.40m	16.21% ₹ 9.8b
Arun Todarwal	Independent Director	less than a year	₹100.00k	Veri yok
Pranay Godha	Non-Executive Non-Independent Director	1.3yrs	₹300.00k	Veri yok
Priti Puri	Additional Independent Non-Executive Director	1.7yrs	₹850.00k	Veri yok
Anand Kusre	Independent Director	less than a year	₹100.00k	Veri yok

1.3yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 506690 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 1.3 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Unichem Laboratories Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

High number of new directors

Unichem Laboratories Limited, Annual General Meeting, Aug 08, 2024

Unichem Laboratories Limited Announces the Resignation of Sandip Ghume as Deputy Chief Financial Officer, Effective June 30, 2024

Unichem Laboratories Limited, Annual General Meeting, Sep 25, 2023

Insider recently sold ₹12m worth of stock

Unichem Laboratories Limited Announces the Resignation of Dilip Kunkolienkar as Member of the Audit Committee and Risk Management Committee of the Board of Directors

Recent updates

Second quarter 2025 earnings released: EPS: ₹4.34 (vs ₹3.48 loss in 2Q 2024)

Unichem Laboratories Limited to Report Q2, 2025 Results on Nov 13, 2024

Unichem Laboratories Limited to Report Q1, 2025 Results on Aug 08, 2024

High number of new directors

Full year 2024 earnings released: ₹10.01 loss per share (vs ₹28.72 loss in FY 2023)

Unichem Laboratories Limited, Annual General Meeting, Aug 08, 2024

Axsome Therapeutics, Inc. Settles Sunosi (solriamfetol) Patent Litigation with Unichem Laboratories Ltd

Unichem Laboratories Limited Announces the Resignation of Sandip Ghume as Deputy Chief Financial Officer, Effective June 30, 2024

Full year 2024 earnings released: ₹10.01 loss per share (vs ₹28.72 loss in FY 2023)

Unichem Laboratories Limited to Report Q4, 2024 Results on May 22, 2024

Third quarter 2024 earnings released: EPS: ₹11.93 (vs ₹9.08 loss in 3Q 2023)

Unichem Laboratories Limited to Report Q3, 2024 Results on Feb 05, 2024

Unichem Laboratories Limited Receives Anda Approval for Its Doxazosin Tablets USP, 1 Mg, 2 Mg, 4 Mg and 8 Mg

Second quarter 2024 earnings released: ₹3.48 loss per share (vs ₹10.04 loss in 2Q 2023)

Unichem Laboratories Limited to Report Q2, 2024 Results on Nov 01, 2023

Unichem Laboratories Limited, Annual General Meeting, Sep 25, 2023

Insider recently sold ₹12m worth of stock

Unichem Laboratories Limited Announces the Resignation of Dilip Kunkolienkar as Member of the Audit Committee and Risk Management Committee of the Board of Directors

Insider recently sold ₹1.5m worth of stock

First quarter 2024 earnings released: ₹0.09 loss per share (vs ₹3.32 loss in 1Q 2023)

Non-Executive Independent Director recently sold ₹10m worth of stock

Full year 2023 earnings released: ₹28.72 loss per share (vs ₹4.70 profit in FY 2022)

Third quarter 2023 earnings released: ₹9.08 loss per share (vs ₹2.01 loss in 3Q 2022)

Krka Reportedly Eyes Promoter Stake in Unichem Laboratories

Insufficient new directors

Second quarter 2023 earnings released: ₹10.04 loss per share (vs ₹1.82 loss in 2Q 2022)

Unichem Laboratories Limited to Report Q2, 2023 Results on Nov 11, 2022

Unichem Laboratories Limited Receives ANDA Approval for Extended Phenytoin Sodium Capsules USP, 100 Mg from United States Food and Drug Administration

Unichem Laboratories Limited Receives ANDA Approval for Carbamazepine Tablets USP

Unichem Laboratories Limited Receives ANDA Approval for Its Quetiapine Extended-Release Tablets

Unichem Laboratories Limited Receives ANDA Approval for its Labetalol Hydrochloride Tablets, USP 100 Mg, 200 Mg, and 300 Mg from the United States Food and Drug Administration

Unichem Laboratories Limited to Report Q1, 2023 Results on Aug 09, 2022

Upcoming dividend of ₹4.00 per share

Full year 2022 earnings released: EPS: ₹4.70 (vs ₹4.88 in FY 2021)

Unichem Laboratories Limited, Annual General Meeting, Aug 09, 2022

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Unichem Laboratories Limited Recommends Final Dividend for the Year Ended March 31, 2022

Unichem Laboratories Limited to Report Q4, 2022 Results on May 27, 2022

Insufficient new directors

Unichem Laboratories Limited Receives ANDA Approval for Its Divalproex Sodium Extended-Release Tablet

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2022 earnings released: ₹1.82 loss per share (vs ₹1.24 profit in 2Q 2021)

Upcoming dividend of ₹4.00 per share

Full year 2021 earnings released: EPS ₹4.88 (vs ₹8.55 loss in FY 2020)

Unichem Laboratories Limited Receives Tentative USFDA Approval for ANDA of Aripiprazole Tablets

Full year 2021 earnings released: EPS ₹4.88 (vs ₹8.55 loss in FY 2020)

Unichem Laboratories Limited Recommends Dividend for the Year Ended March 31, 2021

Unichem Laboratories Limited Announces That It Has Received ANDA Approval for its Amitriptyline HCl Tablets USP, 10 mg, 25 mg, 50 mg, 75 mg, 100 mg and 150 mg

Insider recently bought ₹2.3m worth of stock

Unichem Laboratories Limited Receives ANDA Approval for Its Guanfacine Tablets, USP 1 Mg and 2 Mg from the United States Food and Drug Administration

New 90-day high: ₹332

Unichem Laboratories Limited Receives Anda Approval for Its Apremilast Tablets, 10 Mg, 20 Mg and 30 Mg from the United States Food and Drug Administration

New 90-day high: ₹294

Third quarter 2021 earnings released: EPS ₹3.35 (vs ₹2.07 loss in 3Q 2020)

Unichem Laboratories Limited Receives ANDA Approval for its Zonisamide Capsules, USP 25 mg, 50 mg and 100 mg from USFDA

Unichem Laboratories Limited to Report Q3, 2021 Results on Jan 30, 2021

New 90-day high: ₹286

Unichem Laboratories Limited Receives ANDA Approval from USFDA for Unichem's Celecoxib Capsules, 50 Mg, 100 Mg, 200 Mg, and 400 Mg

New 90-day high: ₹285

Unichem Laboratories Limited Receives ANDA Approval for Atenolol and Chlorthalidone Tablet

New 90-day low: ₹237

Second quarter 2021 earnings released: EPS ₹1.24

First half earnings released

Upcoming Dividend of ₹4.00 Per Share

First quarter earnings released

New 90-day high - ₹214

CEO Tazminat Analizi

CEO

Görev süresi